Status:

RECRUITING

Fluorescence-guided Resection Of Colorectal Liver Metastases Using SGM-101 and Indocyanine GREEN

Lead Sponsor:

Leiden University Medical Center

Conditions:

Colorectal Cancer

Liver Metastasis Colon Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This will be the first trial testing the feasibility of working simultaneously with the two fluorescent dyes ICG and SGM-101 in 10 patients with colorectal metastases.

Detailed Description

25-30% of patients with colorectal cancer develop colorectal liver metastases (CRLM). Cornerstone for optimal survival is achieving radical surgical resections of all metastases . To assist the surgeo...

Eligibility Criteria

Inclusion

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • Diagnosed with liver metastases of colorectal origin for which surgical resection is proposed and meet at least one of the following criteria:
  • Scheduled for surgical resection of \>3 CRLM or;
  • completed neo-adjuvant therapy, of which the last course was completed within 3 months before surgery or;
  • Scheduled for surgery because of a locally recurrent liver metastasis.
  • ≥18 years old.
  • Willing and capable to give informed consent before study specific procedures

Exclusion

  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • Patients with contraindications for SGM-101
  • History of any anaphylactic shock;
  • Patients pregnant or breastfeeding (pregnancy should be ruled out by a pregnancy test within two weeks prior to administration of the conjugate);
  • Known positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAG) or hepatitis C virus (HCV) antibody or patients with untreated serious infections;
  • Previous administration of SGM-101
  • Patients with contraindications for Indocyanine green:
  • Allergy for shells and/or clamps
  • Hyperthyroidism
  • Known allergy for ICG
  • Any condition that the investigator considers to be potentially jeopardizing the patient's well-being or the study objectives

Key Trial Info

Start Date :

December 1 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 1 2025

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT05965817

Start Date

December 1 2023

End Date

May 1 2025

Last Update

May 9 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Leiden University Medical Center

Leiden, Netherlands, 2333ZA